Description: Paradigm Biopharmaceuticals Limited is a biopharmaceutical company focused on repurposing the drug pentosan polysulfate sodium (PPS) for the treatment of inflammation. The Company is engaged in researching and developing therapeutic products for human use. The Company is a drug repurposing company, which seeks to find new uses for old drugs. The Company has commenced the open labelled Phase II clinical trial, investigating the role of the drug PPS in treating traumatic Bone Marrow Lesions. The Company's Rhinosul has properties consisting of both histamine stabilizing and anti-inflammatory properties. The Company focuses on repurposing PPS under ZILOSUL name, as a treatment for bone marrow edema (BME) lesions following traumatic injury.
Home Page: www.paradigmbiopharma.com
PAR Technical Analysis
T. Rowe Price Retirement Funds, Inc.
,
Phone:
61 3 9629 5566
Officers
| Name | Title |
|---|---|
| Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC | Founder, MD & Exec. Chairman |
| Dr. Donna L. Skerrett M.D., MS | Chief Medical Officer and Exec. Director |
| Mr. Justin Cahill | Chief Financial Officer |
| Dr. Ravi Krishnan | Chief Scientific Officer |
| Mr. Simon White | Director of Investor Relations |
| Dr. Michael Imperiale | Global Head of Drug Safety & MPS |
| Ms. Beverley Huttmann | Commercial Head |
| Ms. Michelle Coffey | Global Head of Regulatory Affairs |
| Dr. Mukesh Ahuja | Global Clinical Head of OA |
| Mr. Marco Polizzi | Exec. Officer |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.8239 |
| Price-to-Sales TTM: | 4676.7607 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |